Press releases
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
- IGC Pharma Adds Advisor in Artificial Intelligence
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
- IGC Pharma Reports Third Quarter Fiscal 2024 Results
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
More ▼
Key statistics
As of last trade IGC Pharma Inc (IGS1:BER) traded at 0.34, -16.67% below its 52-week high of 0.408, set on Sep 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 0.33 |
Offer | 0.344 |
Previous close | 0.34 |
Average volume | -- |
---|---|
Shares outstanding | 66.54m |
Free float | 52.94m |
P/E (TTM) | -- |
Market cap | 30.38m USD |
EPS (TTM) | -0.2479 USD |
Data delayed at least 15 minutes, as of Mar 20 2024 07:02 BST.
More ▼